Challenges in severe asthma: Do we need new drugs or new biomarkers?
Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biol...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.921967/full |
| _version_ | 1811258600456192000 |
|---|---|
| author | Adil Adatia Harissios Vliagoftis Harissios Vliagoftis |
| author_facet | Adil Adatia Harissios Vliagoftis Harissios Vliagoftis |
| author_sort | Adil Adatia |
| collection | DOAJ |
| description | Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biologicals, leading to significant interest in biomarkers to guide treatment. Some severe asthmatics remain suboptimally controlled despite trials of biologicals and many of these patients still require chronic systemic corticosteroids. New therapeutics are currently in development to address this unmet need. However, whether these patients could be better treated by using novel biomarkers that inform selection among currently available biologics, and that objectively measure disease control is unclear. In this review, we examine the currently used biomarkers that guide severe asthma management and emerging biomarkers that may improve asthma therapy in the future. |
| first_indexed | 2024-04-12T18:16:51Z |
| format | Article |
| id | doaj.art-6fcf1551c3db4481b4a4e187c7164676 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-12T18:16:51Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-6fcf1551c3db4481b4a4e187c71646762022-12-22T03:21:34ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-09-01910.3389/fmed.2022.921967921967Challenges in severe asthma: Do we need new drugs or new biomarkers?Adil Adatia0Harissios Vliagoftis1Harissios Vliagoftis2Department of Medicine, University of Alberta, Edmonton, AB, CanadaDepartment of Medicine, University of Alberta, Edmonton, AB, CanadaAlberta Respiratory Centre, University of Alberta, Edmonton, AB, CanadaSevere asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biologicals, leading to significant interest in biomarkers to guide treatment. Some severe asthmatics remain suboptimally controlled despite trials of biologicals and many of these patients still require chronic systemic corticosteroids. New therapeutics are currently in development to address this unmet need. However, whether these patients could be better treated by using novel biomarkers that inform selection among currently available biologics, and that objectively measure disease control is unclear. In this review, we examine the currently used biomarkers that guide severe asthma management and emerging biomarkers that may improve asthma therapy in the future.https://www.frontiersin.org/articles/10.3389/fmed.2022.921967/fullsevere asthmabiomarkersbiologicseosinophilsanti-IL 5 |
| spellingShingle | Adil Adatia Harissios Vliagoftis Harissios Vliagoftis Challenges in severe asthma: Do we need new drugs or new biomarkers? Frontiers in Medicine severe asthma biomarkers biologics eosinophils anti-IL 5 |
| title | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
| title_full | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
| title_fullStr | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
| title_full_unstemmed | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
| title_short | Challenges in severe asthma: Do we need new drugs or new biomarkers? |
| title_sort | challenges in severe asthma do we need new drugs or new biomarkers |
| topic | severe asthma biomarkers biologics eosinophils anti-IL 5 |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.921967/full |
| work_keys_str_mv | AT adiladatia challengesinsevereasthmadoweneednewdrugsornewbiomarkers AT harissiosvliagoftis challengesinsevereasthmadoweneednewdrugsornewbiomarkers AT harissiosvliagoftis challengesinsevereasthmadoweneednewdrugsornewbiomarkers |